IL-23-targeting biologics, including Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab, are mainly prescribed for managing psoriasis, a long-lasting autoimmune condition characterized by skin inflammation and irregular cell proliferation. The gene discussed is IL37; the disease is psoriasis.